hepat
viru
hav
wide
spread
pathogen
agent
common
caus
acut
hepat
worldwid
passiv
immun
hav
play
extrem
import
role
postexposur
prophylaxi
clinic
applic
often
requir
larg
amount
antibodi
altern
vitro
product
recombin
protein
express
monoclon
antibodi
mab
milk
transgen
anim
current
use
associ
low
product
cost
high
activ
paper
eight
founder
line
transgen
mice
gener
comicroinject
two
cassett
encod
heavyand
lightchain
neutral
antihav
antibodi
respect
express
heavyand
lightchain
mab
correctli
assembl
modifi
mammari
gland
detect
western
blot
high
express
level
antibodi
achiev
lactat
period
found
independ
copi
number
integr
transgen
highest
level
mgml
bind
specif
neutral
activ
express
mab
assay
elisa
neutral
test
show
capabl
neutral
jn
strain
hepat
viru
effici
therefor
result
suggest
largescal
effici
product
antihav
mab
milk
transgen
farm
anim
would
feasibl
futur
hepat
term
first
introduc
krugman
et
al
krugman
et
al
still
moderatetohigh
risk
hepat
major
world
popul
victor
et
al
approxim
million
case
hepat
occur
everi
year
worldwid
predominantli
develop
countri
di
giammarino
dienstag
consequ
respons
substanti
econom
burden
societi
term
direct
treatment
cost
indirect
product
lose
keyston
hershey
diseas
caus
hepat
viru
hav
belong
genu
hepatoviru
picornavirida
famili
primarili
infect
hepatocyt
caus
effect
rang
slight
symptom
fever
anorexia
nausea
death
fulmin
hepat
martin
lemon
transmiss
hav
mainli
faecalor
rout
contamin
water
food
global
perspect
hadler
et
al
howev
area
eg
unit
state
common
report
sourc
infect
household
close
contact
infect
person
victor
et
al
hepat
vaccin
licens
sinc
current
provid
preexposur
protect
hav
infect
cdc
longterm
protect
highli
immunogen
children
adult
van
damm
van
herck
administr
immunoglobulin
ig
provid
shortterm
effect
protect
larrald
et
al
mainli
peopl
expos
high
risk
infect
peopl
travel
place
viru
endem
close
person
contact
hepat
patient
kim
et
al
furthermor
ig
product
recommend
postexposur
prophylaxi
unit
state
ig
administ
intramuscularli
product
use
prevent
hav
infect
cdc
howev
ig
hav
mainli
deriv
human
plasma
led
limit
suppli
possibl
healthi
risk
due
impur
therefor
applic
human
monoclon
antibodi
mab
consid
altern
approach
hav
infect
mab
proven
wellcharacter
highli
effect
product
better
activ
polyclon
counterpart
lonberg
marasco
sui
nearli
year
develop
mab
progress
play
import
role
therapeut
strategi
reichert
et
al
accordingli
rapidli
grow
market
demand
driven
wide
rang
mab
applic
even
conserv
predict
mab
probabl
global
sale
billion
year
gottschalk
platform
mab
product
variabl
critic
owe
signific
impact
level
qualiti
product
keefer
mab
approv
commerci
current
produc
mammalian
cell
cultur
howev
system
face
shortag
product
capac
scaleup
product
inevit
associ
extrem
high
cost
besid
differ
cultur
condit
pitfal
complic
purif
step
well
variabl
mab
level
posttransl
modif
castillo
farid
kozlowski
swann
winokur
stapleton
limit
motiv
research
develop
altern
product
technolog
higher
effici
technolog
advanc
genet
engin
open
way
costeffect
largescal
product
mab
use
mammari
gland
transgen
anim
method
capabl
high
level
express
low
cost
associ
requir
complex
posttransl
modif
constant
secret
stabl
bioactiv
protein
thu
product
system
avoid
pitfal
associ
express
system
make
transgen
product
mab
attract
dove
dyck
et
al
houdebin
recent
year
mani
success
exampl
mab
express
milk
transgen
mice
product
level
sever
mg
per
ml
mab
coronaviru
hantaviru
molina
et
al
sola
et
al
tang
et
al
yu
et
al
moreov
noteworthi
recombin
human
antithrombin
iii
produc
mammari
gland
transgen
goat
approv
drug
european
medicin
evalu
agenc
emea
launch
atryn
treatment
blood
clot
demonstr
commerci
realiti
protein
massproduct
transgen
anim
therefor
paper
express
human
mab
milk
transgen
mice
explor
potenti
effect
immunoprophylaxi
hav
infect
studi
aim
demonstr
feasibl
largescal
product
mab
hav
milk
transgen
farm
anim
futur
code
region
h
chain
hc
l
chain
lc
gene
human
mab
hav
amplifi
pcr
plasmid
wei
et
al
hc
amplifi
use
primer
hcf
gtctcgagccatggga
hcr
gtctcgagaga
contain
xhoi
site
primer
lcf
gtgtcgacccatgggatg
lcr
gtgtcgacactag
tccctc
ad
sali
site
use
amplifi
lc
two
amplifi
fragment
separ
clone
express
plasmid
digest
xhoi
result
plasmid
design
pbchghc
pbchglc
control
goat
bcasein
regulatori
sequenc
direct
gene
express
specif
mammari
gland
durat
lactat
hghc
hglc
transgen
respect
releas
plasmid
notinrui
noti
sali
digest
lead
kb
kb
dna
fragment
contain
chicken
bglobin
insul
goat
bcasein
promot
ig
secretori
leader
either
human
gene
intron
vlcj
gene
bcasein
genom
dna
respect
fig
two
fragment
purifi
agaros
gel
electrophoresi
omega
usa
subsequ
comicroinject
molar
ratio
pronuclei
fertil
kunm
white
egg
accord
standard
protocol
genom
dna
extract
tail
biopsi
mice
describ
previous
hogan
et
al
presenc
transgen
identifi
pcr
primer
pbcf
gattgacaagt
pbcr
catc
primer
specif
bcasein
intron
intron
sequenc
could
therefor
detect
heavi
light
chain
gene
simultan
genom
dna
lg
digest
ecori
analyz
southern
blot
sambrook
russel
hybrid
probe
label
p
dctp
probe
amplifi
product
kb
hc
kb
lc
gene
transgen
copi
number
determin
signal
quantif
via
phosphorimag
storm
molecular
dynam
sunnyval
ca
total
rna
isol
use
trizol
tiangen
cn
mammari
gland
tissu
three
femal
transgen
mice
lactat
period
one
microgram
total
rna
use
firststrand
cdna
synthesi
use
mmlv
revers
transcriptas
progema
usa
reaction
carri
h
oligodt
total
volum
primer
use
detect
chimer
mrna
express
tccattcagcttct
cctt
vhr
cctcggctctcaga
ttgt
tccattcagcttctc
ctt
vlr
gacttggagccaga
gaat
complementari
exon
goat
bcasein
gene
vregion
hc
lc
amplifi
bp
bp
fragment
respect
mous
bactin
use
rtpcr
intern
control
primer
mous
bactin
bactin
f
bactin
r
ggtgttgaaggtctcaaacat
amplifi
bp
fragment
milk
transgen
mice
nontransgen
mice
collect
day
lactat
dilut
distil
water
defat
elisa
microtitr
plate
coat
goat
antihuman
fab
sigma
us
incub
overnight
wash
pb
contain
pbst
well
block
bsa
pbst
h
room
temperatur
one
hundr
microlit
milk
sampl
ad
per
well
twofold
serial
dilut
respect
incub
wash
plate
incub
hrpconjug
goat
antihuman
igg
fc
antibodi
sigma
us
dilut
per
well
standard
curv
gener
use
twofold
serial
dilut
purifi
human
igg
colorimetr
reaction
develop
substrat
tmb
pierc
us
absorb
valu
measur
nm
plate
wash
six
time
pbst
step
incub
carri
room
temperatur
h
specif
bind
activ
milk
sampl
hav
antigen
determin
elisa
use
purifi
hepat
antigen
cao
et
al
coat
microtitr
plate
hrpconjug
antihuman
fc
specif
antibodi
dilut
use
antibodi
mgml
express
cho
cell
use
posit
control
vitro
neutral
activ
test
neutral
activ
hav
determin
modifi
cell
cultur
assay
base
macgregor
et
al
first
hav
jn
strain
dilut
step
determin
tissu
cultur
infect
dose
tcid
fetal
rhesu
monkey
kidney
cell
titr
infecti
viru
determin
base
tcid
endpoint
hav
use
follow
experi
milk
sampl
initi
dilut
concentr
close
mgml
milk
sampl
recombin
purifi
antibodi
posit
control
mgml
dilut
use
twofold
dilut
incub
ml
viru
h
separ
four
replic
sampl
inocul
onto
monolay
cell
grow
well
plate
mock
infect
cell
includ
hav
neg
control
addit
hav
viru
titr
also
measur
elisa
plate
incub
h
medium
remov
ml
fresh
cultur
medium
ad
well
plate
monolay
incub
day
cultur
medium
replac
everi
day
cell
harvest
day
ml
pb
plu
disrupt
three
cycl
freezethaw
presenc
hav
monitor
elisa
condit
polyclon
human
antihav
antibodi
cdc
cn
use
coat
antibodi
hrpconjug
polyclon
human
antihav
antibodi
cdc
cn
use
detect
antibodi
neutral
endpoint
calcul
reed
muench
gener
transgen
mice
express
antihav
mab
high
level
milk
two
separ
cassett
construct
encod
igg
hc
lc
gene
control
goat
bcasein
promot
fig
two
cassett
coinject
fertil
mous
egg
four
male
femal
transgen
founder
obtain
mice
analyz
pcr
fig
contain
hc
lc
transgen
addit
anoth
five
founder
contain
either
hc
lc
transgen
analyz
southern
blot
use
confirm
transgen
integr
genom
eight
transgen
mice
fig
well
determin
transgen
copi
number
probe
specif
kb
hc
kb
lc
fragment
mix
togeth
allow
transgen
detect
simultan
enabl
comparison
rel
copi
number
copi
number
transgen
eight
founder
differ
rang
hc
lc
compar
band
intens
known
amount
control
plasmid
tabl
six
transgen
founder
die
mate
wild
type
mice
transmit
transgen
offspr
total
transgen
mice
identifi
among
offspr
contain
doubl
transgen
remain
contain
either
hc
lc
transgen
probabl
reflect
multipl
integr
loci
founder
anim
hc
lc
transgen
mrna
express
mammari
gland
lactat
transgen
mice
analyz
rtpcr
fig
found
hc
lc
transgen
express
femal
three
detect
transgen
line
mice
result
confirm
recombin
mab
express
chimer
mrna
contain
untransl
exon
goat
bcasein
gene
milk
sampl
collect
five
transgen
founder
mice
mice
carri
transgen
structur
express
antihav
mab
milk
analyz
western
blot
singl
band
detect
hc
lc
reduc
condit
expect
molecular
weight
mw
kda
hc
kda
lc
respect
fig
result
indic
presenc
hc
lc
express
detect
tabl
c
rtpcr
analysi
transgen
express
mammari
gland
tissu
transgen
mice
rtpcr
perform
demonstr
presenc
chimer
mrna
bp
ladder
transgen
mice
nc
nontransgen
mous
mous
bactin
gene
use
intern
control
line
transgen
milk
sampl
also
analyz
nonreduc
condit
show
strong
band
mw
kda
fig
rel
molecular
mass
major
detect
band
ident
purifi
human
igg
indic
recombin
mab
assembl
modifi
correctli
transgen
mice
howev
addit
weak
band
lower
mw
also
observ
probabl
reflect
presenc
incomplet
assembl
igg
molecul
stabil
mab
product
milk
also
detect
analyz
eight
mice
gener
four
transgen
line
within
line
amount
mab
constant
data
shown
result
may
due
cointegr
transgen
chromosom
founder
assess
express
level
recombin
mab
skim
milk
obtain
day
lactat
period
four
differ
transgen
line
line
measur
use
elisa
approach
specif
human
igg
fab
fragment
four
line
shown
express
antihav
mab
higher
mgml
highest
level
mgml
line
show
low
express
level
tabl
appar
differ
express
mab
observ
milk
sampl
collect
day
collect
day
line
data
shown
bind
specif
milk
sampl
hav
antigen
examin
elisa
expect
milk
sampl
could
bind
hav
antigen
dosedepend
manner
affin
hav
appear
equival
except
line
nearli
bind
specif
choderiv
igg
fig
highest
antibodi
titer
could
reach
concentr
ngml
evalu
neutral
activ
mab
milk
two
high
express
transgen
line
line
assay
neutral
test
base
abil
block
hav
infect
cell
dilut
transgen
skim
milk
consid
virusneutr
activ
less
cell
infect
hav
shown
three
transgen
milk
sampl
exhibit
neutral
activ
hav
dosedepend
manner
fig
particular
milk
sampl
mous
reduc
hav
infect
dilut
milk
sampl
mice
reduc
hav
infect
differ
transgen
mice
nc
neg
control
milk
nontransgen
mice
pc
posit
control
purifi
human
igg
fig
elisa
detect
express
mab
bind
activ
hav
antigen
dilut
milk
sampl
three
transgen
line
mice
femal
nontransgen
mous
neg
control
ad
microtitr
well
coat
hav
specif
detect
hrpconjug
antihuman
fc
specif
antibodi
legend
denot
correspond
milk
sampl
collect
day
lactat
respect
choderiv
antibodi
mgml
recogn
hav
antigen
use
posit
control
valu
present
od
valu
nm
dilut
milk
sampl
mous
concentr
recombin
mab
requir
protect
estim
lgml
dilut
obviou
differ
observ
neutral
activ
among
detect
milk
sampl
addit
protect
level
similar
contrast
milk
sampl
nontransgen
mice
viru
neutral
capac
test
dilut
toward
engin
passiv
immun
order
protect
hav
infect
human
be
transgen
mice
model
express
human
antihav
mab
construct
paper
demonstr
hc
lc
antihav
antibodi
express
milk
transgen
mice
control
goat
bcasein
promot
well
properli
assembl
function
igg
molecul
hav
incorpor
two
strategi
vector
design
enhanc
transgen
express
first
chicken
bglobin
insul
predict
reduc
influenc
neighbor
regulatori
element
therebi
modul
posit
effect
caus
random
integr
transgen
host
chromosom
chung
et
al
secondli
genom
rather
cdna
fragment
igg
constant
region
use
benefit
potenti
enhancerlik
effect
intron
whitelaw
et
al
high
level
mab
express
observ
consist
result
use
two
strategi
though
posit
effect
eg
line
extrem
low
express
level
still
observ
furthermor
mice
carri
transgen
howev
mate
founder
transgen
mice
nontransgen
mice
result
singl
chain
transgen
offspr
might
due
segreg
transgen
differ
chromosom
site
founder
major
transgen
founder
transmit
transgen
offspr
agre
previou
studi
report
comicroinject
normal
led
transgen
cointegr
singl
chromosom
site
clark
et
al
tang
et
al
amount
express
mab
estim
elisa
milk
reveal
express
level
higher
mammalian
express
system
highest
express
level
mgml
express
level
consider
higher
previous
report
milk
transgen
mice
mgml
limonta
et
al
mgml
kolb
et
al
mgml
newton
et
al
mgml
mg
ml
express
level
maintain
lactat
period
valid
fact
goat
bcasein
promot
could
stabli
drive
high
level
express
recombin
protein
mammari
gland
lactat
stage
young
et
al
direct
relationship
transgen
copi
number
amount
mab
observ
detect
transgen
mice
impli
integr
site
transgen
greater
effect
express
level
transgen
copi
number
tabl
consist
previou
find
like
therapeut
recombin
protein
character
mab
well
order
ensur
structur
function
activ
specif
experi
presenc
addit
weak
band
western
blot
nonreduc
condit
indic
small
portion
incomplet
fold
igg
molecul
sever
explan
propos
interpret
phenomenon
suggest
like
explan
relat
presenc
free
sulfhydryl
mab
zhang
czupryn
comparison
specif
activ
recombin
mab
hav
neutral
serial
dilut
milk
sampl
initi
dilut
concentr
mgml
two
transgen
line
mice
femal
nontransgen
mous
neg
control
assay
hav
jn
strain
choderiv
haig
mgml
antibodi
use
posit
control
transgen
re
igg
molecul
consist
two
heavi
two
light
chain
coval
link
interchain
disulfid
bond
addit
domain
heavi
light
chain
contain
one
addit
disulfid
bond
mab
speci
contain
free
sulfhydryl
like
form
protein
fold
process
endoplasm
reticulum
consequ
experi
minor
proport
form
recombin
mab
epitheli
cell
mammari
gland
mice
may
lack
interchain
disulfid
bond
remain
noncoval
associ
nonreduc
condit
present
low
mw
fragment
analysi
noteworthili
data
exhibit
signific
advantag
produc
neutral
mab
hav
transgen
milk
highaffin
highspecif
protein
synthesi
compar
previous
studi
propos
product
neutral
mab
hav
use
phagedisplay
antibodi
librari
kim
et
al
antigenbind
activ
mab
demonstr
specif
elisa
repres
nearli
increas
antibodi
affin
viru
neutral
assay
previous
test
choderiv
control
verifi
transgen
milk
produc
mab
effect
neutral
hav
prevent
infect
cell
fig
conclus
gener
transgen
mice
express
high
level
hav
neutral
mab
milk
work
solidifi
concept
use
larger
transgen
anim
product
potenti
therapeut
antihav
antibodi
evergrow
market
need
larg
quantiti
mab
transgen
larg
anim
provid
costcompetit
largescal
product
altern
complex
protein
furthermor
method
also
facilit
commerci
product
mab
use
transgen
bioreactor
immunoprophylaxi
